Clinical Trial Update: Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update describes a Phase 2/3 study of Y-shaped Pegylated Interferon alpha-2a plus Ribavirin for untreated chronic Hepatitis C in Egyptian patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• YPeg-IFNα-2a (Pegylated interferon alpha-2a)

Snippet

Sponsor: BioGeneric Pharma | Conditions: Self Efficacy, Hepatitis C | Phase 2, Phase 3 | Status: UNKNOWN